Significant results from new brain cancer drugs
Filed with ASX · · 4 pages · English
Novel brain cancer drug candidates significantly reduce tumour growth Important ability to cross blood-brain barrier Promising early Chroma™drug candidate for leukaemia Sydney, 3 September 2024:Innovative biotech companyNoxopharm Limited (ASX:NOX)is pleased to announce substantial progress on its Chroma™technology platform, with encouraging brain cancer results plus early work on leukaemia. Gliobl
Earlier from Noxopharm
- Noxopharm Targets Clinical Trial for First-in-Class Drug
- Significant CRO-67 Results in Pancreatic Cancer Studies
- June 2024 Quarterly Activities Report and Appendix 4C
- March 2024 Quarterly Activities Report and Appendix 4C
- Appendix 4D and Half Year 2024 Financial Report
Later from Noxopharm
- Advanced funding secured ahead of R&D rebate
- New funding from sophisticated investors
- September 2024 Quarterly Activities report and Appendix 4C
- Additional convertible note for long-term shareholder
- December 2024 Quarterly Activities Report and Appendix 4C
Follow Noxopharm into a list and get an email when it puts out news.
Follow Noxopharm